ARCA biopharma, Inc. (NASDAQ:ABIO – Get Rating) shares passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.28 and traded as low as $2.06. ARCA biopharma shares last traded at $2.10, with a volume of 8,556 shares trading hands.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on shares of ARCA biopharma in a research note on Friday. They set a “sell” rating on the stock.
ARCA biopharma Trading Up 1.0 %
The business’s 50 day moving average is $2.09 and its two-hundred day moving average is $2.28. The company has a market cap of $30.26 million, a PE ratio of -2.08 and a beta of 1.82.
Institutional Inflows and Outflows
ARCA biopharma Company Profile
ARCA biopharma, Inc, a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure.
- Get a free copy of the StockNews.com research report on ARCA biopharma (ABIO)
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.